Pharmaceutical industry payments to healthcare professional organisations in the United Kingdom: a seven-year cross-sectional analysis of the Disclosure UK database from 2015 to 2021

Abstract

Objectives

This study aimed to examine the size and trends in payments from the pharmaceutical industry to healthcare professional organisations (HPOs) in the United Kingdom (UK), and to characterise the conflict of interest (COI) management plans by HPOs who received large payments.

Design

Cross-sectional analysis of non-research payments disclosed in the Disclosure UK database from 2015 to 2021.

Setting

United Kingdom.

Participants

148 pharmaceutical companies disclosing payment data and HPOs receiving the largest payments.

Main outcome measures

Total value and median of payments per HPO; existence and content of COI policies among HPOs receiving the largest payments.

Results

A total of 898 HPOs received non-research payments worth £99.9 million (17.4% of non-research payments to all healthcare organisations). The median seven-year payment per HPO was £4509 (interquartile range: £943–£30,360). The annual payments nearly doubled from £9.3 million in 2015 to £17.6 million in 2021. Event payments constituted the largest share (£68.2 million, 68.2%). HPOs representing physicians received over 91.5% (£91.5 million) of all payments, while those related to endocrinology and diabetology – 16.3% (£16.3 million). Over 59.9% (£59.9 million) went to the 30 top-funded HPOs, of which only 17 (56.7%) had a publicly accessible COI policy. However, just 6 (35.3%) of these policies included provisions for payments from external organisations.

Conclusions

HPOs received nearly one-fifth of pharmaceutical company payments to the UK healthcare sector. These payments were concentrated among a small number of HPOs, which often lacked effective policies for management of COI and payments from the industry.

Keywords

Codes of professional ethics competing interests (ethics)ethics health policy

Get full access to this article

View all access options for this article.

References

Rothman

McDonald

Berkowitz

Chimonas

DeAngelis

Hale

, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009; 301: 1367–1372.

Rosenbaum

Conflicts of interest: part 1: reconnecting the dots – reinterpreting industry-physician relations. N Engl J Med 2015; 372: 1860–1864.

Lexchin

Sponsorship of Canadian professional medical societies by drug, medical device and medical technology companies: a cross-sectional study. J Gen Intern Med 2022; 37: 4280–4282.

Lexchin

Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study. JRSM Open 2022; 13: 20542704221111243.

Murayama

Higuchi

Senoo

Financial relationships between pharmaceutical companies and internal medicine societies. JAMA Netw Open 2024; 7: e244777.

Nejstgaard

Bero

Hrobjartsson

Jørgensen

, et al. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ 2020; 371: m4234.

Murayama

Evaluation of research and non-research industry payments to endocrinologists in the United States: an analysis of the Open Payments Database from 2014 to 2022. Diabet Med 2024; 41: e15253.

Murayama

Nine-year analysis of industry payments to geriatricians in the United States between 2014 and 2022. J Am Med Dir Assoc 2023; 25: 104840.

Mulinari

Martinon

Jachiet

Ozieranski

Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries. Health Policy 2021; 125: 915–922.

10.

Fabbri

Santos

Mezinska

, Mulinari S and Mintzes B. Sunshine policies and murky shadows in Europe: disclosure of pharmaceutical industry payments to health professionals in nine European countries. Int J Health Policy Manag 2018; 7: 504–509.

11.

Ozieranski

Csanadi

Rickard

Tchilingirian

Mulinari

Analysis of pharmaceutical industry payments to UK health care organizations in 2015. JAMA Netw Open 2019; 2: e196253.

12.

Boytchev

Medical royal colleges receive millions from drug and medical devices companies. BMJ 2023; 382: 1658.

13.

Association of the British Pharmaceutical Industry. Code of Practice for the Pharmaceutical Industry 2021. See www.pmcpa.org.uk/the-code/2021-interactive-abpi-code-of-practice/ (last checked 26 February 2024).

14.

Ozieranski

Saito

Rickard

Mulinari

Ozaki

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Global Health 2023; 19: 14.

15.

Ozieranski

Martinon

Jachiet

Mulinari

Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe. Int J Health Policy Manag 2022; 11: 2842–2859.

16.

Uppal

Anderson

TS.

Changes in industry marketing and research payments to US physicians and teaching hospitals during the COVID-19 pandemic. JAMA Health Forum 2022; 3: e223342.

17.

Mulinari

Ozieranski

Unethical pharmaceutical marketing: a common problem requiring collective responsibility. BMJ 2023; 382: e076173.

18.

Ozieranski

Saghy

Mulinari

Pharmaceutical industry payments to NHS trusts in England: a four-year analysis of the disclosure UK database. PLoS One 2023; 18: e0290022.

19.

Saghy

Mulinari

Ozieranski

Drug company payments to General Practices in England: cross-sectional and social network analysis. PLoS One 2021; 16: e0261077.

20.

Ozieranski

Rickard

Mulinari

Exposing drug industry funding of UK patient organisations. BMJ 2019; 365: l1806.

21.

Tringale

Marshall

Mackey

Connor

Murphy

Hattangadi-Gluth

JA.

Types and distribution of payments from industry to physicians in 2015. JAMA 2017; 317: 1774–1784.

22.

Zhang

Anderson

TS.

Comparison of industry payments to physicians and advanced practice clinicians. JAMA 2022; 328: 2452–2455.

23.

Mitchell

Dusetzina

Mishra Meza

Trivedi

Bach

Winn

Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study. BMJ 2023; 383: e075512.

24.

Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: The National Academies Press, 2009:436.

25.

Rothman

Chimonas

Academic medical centers' conflict of interest policies. JAMA 2010; 304: 2294–2295.

26.

Lenzer

Hoffman

Furberg

Ioannidis

JPA.

Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ 2013; 347: f5535.

27.

Tzortziou Brown

McCartney

Talaga

Huxtable

Papanikitas

David-Barrett

Policies on doctors' declaration of interests in medical organisations: a thematic analysis. J R Soc Med 2023; 116: 295–306.

28.

Taheri

Kirubarajan

Lam

Taheri

Olivieri

NF.

Discrepancies in self-reported financial conflicts of interest disclosures by physicians: a systematic review. BMJ Open 2021; 11: e045306.

29.

Ozieranski

Mulinari

Broken beyond repair: self regulation of industry payments to clinicians and hospitals. BMJ 2024; 386: q1559.

30.

Moynihan

Bero

Hill

Johansson

Lexchin

Macdonald

, et al. Pathways to independence: towards producing and using trustworthy evidence. BMJ 2019; 367: l6576.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.51 MB